Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy

Miller, Tom R.; Grigsby, Perry W.

doi:10.1016/s0360-3016(02)02705-0

Cited by 268 publications

(175 citation statements)

References 22 publications

Supporting

Mentioning

164

Contrasting

Unclassified

Order By: Relevance

“…1,2 Tumor volume, which also is correlated with survival, can be directly assessed with FDG-PET. 6 Miller and Grigsby examined 51 patients who underwent PET studies before treatment. Using correlational CT scans from 13 patients in preliminary studies, they identified a fixed threshold fraction of the peak activity in the tumor and by simple count thresholding were able to identify tumor boundaries.…”

Section: Petmentioning

confidence: 99%

“…Positron emission tomography (PET), in conjunction with 2-[fluorine-1]fluoro-2-deoxy-D-glucose (FDG), has been used in cervical cancer staging and follow-up, [1][2][3][4][5] and it has been valuable in accurately assessing lymph node and distant metastases. 6 Newer, copper-labeled tracers also are expanding the range of uses of PET. In the current report, after a brief discussion of staging, we discuss new developments and their contributions toward improved delineation of tumors and metastases using lymphangiography, ultrasonography, CT, MRI, PET, and lymphatic mapping.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Imaging in cervical cancer

Follen

Levenback

Iyer

et al. 2003

Cancer

129

View full text Add to dashboard Cite

show abstract

Section: Petmentioning

confidence: 99%

mentioning

confidence: 99%

Imaging in cervical cancer

Follen

Levenback

Iyer

et al. 2003

Cancer

129

View full text Add to dashboard Cite

show abstract

“…Prognostic stratification provided by PET response was both significant and of a similar magnitude in patients with lowand high-grade radio-toxicity [21,22]. Metabolic changes often occur before morphologic changes, metabolic image appear to be valuable tool in response assessment.…”

Section: Ratio Variation For Gray Level Distributionmentioning

confidence: 88%

“…Ratio of gray value distribution in every level among the range of level 11~32 in Figure 3b has an obvious increase comparing Figure 3a and has almost more than one time increase in level 18~32. Then we divided the 32 discrete gray level intervals into three parts as follows: The lower (level 1-10), the middle (level [11][12][13][14][15][16][17][18][19][20][21][22] and the higher (level 23-32). The percentage of each part ratio variation between pretreatment and treatment completion were the lower part (pro: 62.9%-pre: 84.7%) -21.8%, the middle part (28.9%-11%) -17.9% and higher part (8.2%-4.3%) -3.9% for the example patient.…”

Section: Ratio Variation For Gray Level Distributionmentioning

confidence: 99%

Assessing Response to Chemoradiotherapy on 18F-FDG PET Images in Non-Small Cell Lung Cancer using New Approaches of Histogram and Gray Level Co-Occurrence Matrix

Ma¹,

Luo²,

Hou³

et al. 2017

Int J Cancer Clin Res

View full text Add to dashboard Cite

Purpose: To investigate inherent information provided by 18 F-FDG PET to ameliorate shortcomings of relying on visual inspection or sole SUV measurement in treatment assessing. Patients and methods:Twelve patients with newly diagnosed NSCLC and treated with combined Chemoradiotherapy (CRT) were involved in this study. We analyzed the percentage variation of gray value in every gray level or on the whole using histogram analysis algorithm which represents global intensity distribution. We also investigated texture parameters which describe local intensity-spatial distribution and were calculated by Gray Level Co-occurrence Matrix (GLCM). The parameters' variation analysis involved comparison between patient's PET scans of pretreatment and 1 month after treatment completion and correlation between characteristics variation and response degree were analyzed. The texture comparison between the same patient's lesions on one side lung and the corresponding tissue with same size, location on the other side normal lung was involved.Results: The uniformity degree of gray level distribution on the whole and the maximum ratio decrease were well associated with tumor shrinkage and response degree. In that case, they were capable to differentiate tumor response to CRT. Texture parameters' variation characterizing local tumor metabolism was able to differentiate the response if these parameters were taken as indices because they showed great correlation with regional response to CRT. Conclusion:We demonstrated that histogram and texture analysis methods on baseline 18F-FDG PET scans have showed more robust, discriminative in assessing response to combined CRT and may have a good application prospect in clinical practice.

show abstract

“…Despite the fact that in the same paper it was pointed out that the threshold value should not be fixed because it also depends on target size, the fixed threshold approach was adopted in many clinical studies [22][23][24][25][26]. This target size dependence effect has been subsequently investigated by many researchers and found to be real [27][28][29][30].…”

Section: Introductionmentioning

confidence: 99%

Towards Biological Target Volumes Definition for Radiotherapy Treatment Planning: Quo Vadis PET/CT?

Dević¹

2013

J Nucl Med Radiat Ther

View full text Add to dashboard Cite

IntroductionRadiotherapy treatment planning (RTP) over the last few decades has been based on anatomical targets, namely gross tumor volume (GTV) and from it derived clinical target volume (CTV) as well as the planning target volume (PTV). Owing to its superb spatial reproducibility and the ability to provide the information on electron density (useful for heterogeneity corrections), computed tomography (CT) was, and it still represents, the backbone of modern/high technology radiotherapy treatment planning. The lack of sufficient soft tissue contrast in CT resulted in the incorporation of other imaging methods, such as the magnetic resonance imaging (MRI), into the target definition through the process of image co-registration (sometimes incorrectly termed as image fusion). Whereas the MRI has widely contributed to a better definition of the GTV, [1] which represents an anatomical volume, functional information has not been readily available in the framework of conformal 3D treatment planning and delivery in radiotherapy until recently. In addition, it has been widely accepted that a homogeneous dose delivery to the PTV is the standard of care one should pursue to achieve the best local tumor control.Integration of positron emission tomography (PET) and computed tomography (CT) scanners [2][3][4][5] introduced a new dimension in nuclear medicine by combining functional and anatomical imaging in one machine: the PET/CT scanner. Main advantages of PET/CT scanners are:9 Improved quality of reconstructed PET images with the use of a CT map for attenuation correction of emission PET scans 9 Decrease of about half of the PET acquisition time compared to the previous generation of PET scanners, which used an external radioactive source to acquire transmission scan for attenuation correction. In addition, new faster scintillation materials have also contributed to the shortening of the scanning time 9 The combined medical imaging modality is likely helping management of radiotherapy patients 9 Better understanding of tumor metabolic activity spatial localization by the ability to map the distribution of a specific radiopharmaceutical in co-registered PET/CT images, despite the relatively poor spatial resolution of PET image [6,7].With an increased access to PET/CT information and an apparent appreciation that different sections of the tumor functionally do not behave uniformly, radiation oncologists started to contemplate a change in the traditional concept of uniform dose to the PTV delivery. Instead, a notion of biological targeting and dose painting has come into the play. The first question that comes to our attention is how to define the biological target volumes (BTV) and what do they represent? Ten years after the introduction of the PET/CT scanners into the radiation oncology community, target delineation in radiotherapy treatment planning using FDG-PET/CT scans still has a lot of controversy. The aim of this article is to review the limitations of the current methods for the incorporation of FDG based PET/CT ...

show abstract

Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy

Cited by 268 publications

References 22 publications

Imaging in cervical cancer

Imaging in cervical cancer

Assessing Response to Chemoradiotherapy on 18F-FDG PET Images in Non-Small Cell Lung Cancer using New Approaches of Histogram and Gray Level Co-Occurrence Matrix

Towards Biological Target Volumes Definition for Radiotherapy Treatment Planning: Quo Vadis PET/CT?

Contact Info

Product

Resources

About